Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,343.72
(
-0.39%
)
US TECH 100
22,523.20
(
0.86%
)
Dow Jones
45,216.14
(
0.11%
)
Brent Oil
105.67
(
-2.68%
)
Bitcoin
66,409.57
(
-0.44%
)
News Focus
News Focus
Post# of 257314
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122824
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: biopearl post# 97330

Wednesday, 06/16/2010 5:27:15 PM

Wednesday, June 16, 2010 5:27:15 PM

Post# of 257314
Irrespective of the patent ruling you cited, the arena for anti-CD20 biosimilars/Rituxan knockoffs has become unduly crowded, IMO. I completely discount the possibility that GTCB’s CD20 program will generate any value for shareholders.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today